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158Duplex ultrasound diagnosis of failing stent grafts
placed for occlusive disease
Douglas A. Troutman, DO, Nicholas J. Madden, DO, Matthew J. Dougherty, MD, and
Keith D. Calligaro, MD, Philadelphia, Pa
Objective: We previously showed that duplex ultrasound (DU) imaging is beneﬁcial in the diagnosis of failing vein and
prosthetic grafts performed for arterial occlusive disease. The purpose of this study was to evaluate whether DU imaging
can reliably diagnose failing stent grafts (ie, covered stents) placed for arterial occlusive disease.
Methods: Between July 1, 2005, and June 30, 2013, we placed 142 stent grafts in 92 arterial segments (1.5 stent grafts/
stenotic artery) for lower extremity occlusive disease in patients who also underwent at least one DU surveillance study
documenting a patent stent graft. Stent grafts were placed in 29 iliac and 52 femoropopliteal arteries and in 11 failing
infrainguinal bypass grafts. Stent grafts used were Viabahn (W. L. Gore and Associates Inc, Flagstaff, Ariz) in 116 (82%),
Wallgraft (Boston Scientiﬁc, Natick, Mass) in 23 (16%), Fluency (C. R. Bard Inc, Tempe, Ariz) in 2 (1%), and iCast
(Atrium, Hudson, NH) in 1 (1%). Mean follow-up was 16 months (range, 1 week-86 months). Postoperative DU
surveillance was performed in our Intersocietal Accreditation Commission accredited noninvasive vascular laboratory at
1 week, then every 3 months the ﬁrst year, and every 6 months thereafter. DU measured peak systolic velocities (PSVs)
and velocity ratio of adjacent PSVs (Vr) every 5 cm within the stent graft and adjacent arteries.
Results: We retrospectively classiﬁed the following factors as “abnormal DU ﬁndings:” focal PSVs >300 cm/s, uniform
PSVs<50 cm/s throughout the graft, and a Vr >3.0. Fifteen of 20 patients with one ormore of these abnormalDU ﬁndings
underwent prophylactic intervention (n[8) or occludedwithout intervention (n[7),whereas only twoof 72with normal
DU ﬁndings occluded (P [ .0001). Excluding the eight patients who underwent prophylactic intervention, seven of 12
patients with abnormal DU ﬁndings occluded without intervention vs two of 72 with normal DU ﬁndings (P[ .0001).
Conclusions: These ﬁndings suggest that follow-up DU surveillance can predict failure of stent grafts placed for lower
extremity occlusive disease. Focal PSVs >300 cm/s, Vr >3.0, and most importantly, uniform PSVs <50 cm/s throughout
the stent graft were statistically reliable markers for predicting stent graft thrombosis. (J Vasc Surg 2014;60:1580-4.)Duplex ultrasound (DU) protocols are commonly
accepted for postoperative surveillance of arterial vein
bypass grafts and by some interventionalists for prosthetic
bypass grafts.1-4 DU surveillance protocols have been
shown to improve patency rates of arterial bypass grafts.5
An increasing proportion of patients with lower
extremity occlusive disease are treated with endovascular
interventions, including balloon angioplasty, stents, and
stent grafts. Stent grafts are developing a special niche in
the endovascular armamentarium. For the femoropopliteal
segment, stent grafts have been shown to have better
patency than bare-metal stents for long segmental occlusive
disease.6,7 A covered stent can prevent extravasation when
treating heavily calciﬁed iliac lesions while improving
patency compared with a bare-metal stent.8
DU criteria have been established to diagnose stenosis
in de novo arterial lesions and lesions treated with bare-
metal stents.9,10 These DU criteria are similar but not thethe Section of Vascular Surgery, Pennsylvania Hospital.
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0same as DU criteria used for bypass surgery graft surveil-
lance. We believe this is the ﬁrst study to examine DU
criteria for stent grafts placed for lower extremity arterial
occlusive disease.
METHODS
We reviewed all patients treated with stent grafts for
lower extremity occlusive arterial disease by the vascular
surgeons at Pennsylvania Hospital in Philadelphia between
July 1, 2005, and June 30, 2013. Patient consent and
Investigational Review Board approval were not obtained
because we used a deidentiﬁed retrospectively maintained
database. All patients had at least one DU surveillance
study documenting a patent stent graft. DU surveillance
was performed in our Intersocietal Accreditation Commis-
sion accredited noninvasive vascular laboratory. For our
endovascularly treated patients, we performed DU imaging
1 week after the procedure, then every 3 months the ﬁrst
year, and every 6 months thereafter. The initial study dur-
ing the ﬁrst week was performed to establish a baseline in
case of a subsequently abnormal DU scan or clinical
change. The frequency of surveillance was increased or
the patient underwent intervention if noted to have an
“abnormal DU ﬁnding.”
DUwas used to measure peak systolic velocities (PSVs),
the ratio of adjacent PSVs (Vr), and the diameter of the stent
graft and adjacent artery. We retrospectively classiﬁed the
following factors as “abnormal DU ﬁndings:” focal PSVs
>300 cm/s, uniform PSVs<50 cm/s throughout the graft,
Table I. Clinical symptoms of patients undergoing stent
graft placement
Rutherford
class Iliac, No.
Femoropopliteal,
No. Bypass, No.
1 e 1 e
2 7 9 e
3 10 18 5
4 6 10 5
5 6 12 1
6 e 2 e
Table II. Stent graft length and diameter
Variable Iliac Femoropopliteal Bypass
Length, cm 6.8 18.9 11.4
Diameter, mm 7.7 5.9 6.4
Table III. Arterial lesions classiﬁcation according to
TransAtlantic Inter-Society Classiﬁcation for the
Management of Peripheral Arterial Disease (TASC) IIa
Classiﬁcation Iliac, No. Femoropopliteal, No.
TASC A 7 3
TASC B 9 9
TASC C 11 24
TASC D 2 16
aThere were no bypasses with TASC classiﬁcation.
Table IV. Number of patent tibial runoff vesselsa
Runoff vessels Femoropopliteal, No. Bypass, No.
3 17 4
2 12 5
1 22 2
0 1 e
aThere were no iliac runoff vessels.
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 6 Troutman et al 1581or a Vr >3.0. These DU criteria were derived from data on
failing arterial and prosthetic bypass conduits from our pre-
vious studies on lower extremity arterial graft surveillance.1-3
TheDUassessment was performedwith the patient sup-
ine. Imaging was performed from the inﬂow artery to the
outﬂow artery involving the arterial segment treated with
the stent graft. The arteries were measured in the transverse
and longitudinal axes. PSVs and diameter were recorded
every 5 cm with B-mode imaging and spectral Doppler.
DU was performed by registered vascular laboratory tech-
nologists using HD-11 10.4 software (DHI-5000, HDI-
3000; Philips Medical Systems, Bothell, Wash). All patients
were prospectively maintained in our Access computer data-
base (Microsoft Corp, Redmond, Wash). Statistical analysis
was performed with a Fisher exact test, and P values <.05
were considered statistically signiﬁcant.
RESULTS
During this time period, 142 stent grafts were placed in
92 arterial segments (1.5 stent grafts/stenotic artery) in 79
patients for lower extremity occlusive disease. Stent grafts
were placed in 29 iliac arteries, 52 femoropopliteal arteries,
and 11 failing infrainguinal bypass grafts. There was a fairly
even distribution of claudicant patients and those with
limb-threatening ischemia in this series (Table I). Stent
grafts used were Viabahn (W. L. Gore and Associates
Inc, Flagstaff, Ariz) in 116 (82%), Wallgraft (Boston Scien-
tiﬁc, Natick, Mass) in 23 (16%), Fluency in (C. R. Bard Inc,
Tempe, Ariz) in 2 (1%), and iCast (Atrium, Hudson, NH)
in 1 (1%). Even though the types of stent grafts used dur-
ing this series have changed, we concluded this should have
no bearing on the DU results. Mean follow-up was
16 months (range, 1 week-86 months).
The lesion length and diameter of the stent graft used
were signiﬁcantly different for the arterial bed treated. The
length of lesion treated was obtained through a retrospec-
tive review of the operative note and conﬁrmed with thepostoperative DU imaging. The average length of the iliac,
femoropopliteal, and arterial bypass lesions treated was
6.8 cm, 18.9 cm, and 11.4 cm, respectively (P ¼ .0271).
The average diameters of stent grafts placed in the iliac
and femoropopliteal arteries and arterial bypasses were
7.7 mm, 5.9 mm, and 6.4 mm, respectively. (Table II).
The average PSV for stent grafts in all arterial segments
was 131 cm/s (standard deviation, 62 cm/s). The average
(standard deviation) PSVs for iliac, femoropopliteal, and
arterial bypass stent grafts were 148.6 (58.1) cm/s,
109.7 (54.8) cm/s, and 143.1 (75.2) cm/s.
The arterial lesions were classiﬁed according to the
TransAtlantic Inter-Society Classiﬁcation for Management
of Peripheral Arterial Disease (TASC II).11 Most lesions
were TASC C in both the aortoiliac and femoropopliteal
arterial segments (Table III). The arterial bypass stenoses
that were treated with stent grafts were classiﬁed by length
and diameter. We selectively treated failing arterial bypasses
with stent grafts for larger-diameter (>5 mm) bypasses
when the lesions were located at sites that were difﬁcult
to treat with open surgical repair, such as stenoses in
scarred groins or in the adductor canal for bypasses
tunneled anatomically. The number of patent tibial runoff
arteries was recorded for the femoropopliteal and bypass
groups but not for the aortoiliac group (Table IV).
Of 20 stent grafts with one or more abnormal DU
ﬁndings as deﬁned above, 15 underwent prophylactic inter-
vention (n ¼ 8) or occluded without intervention (n ¼ 7),
whereas only two of 72 stent grafts with normal DU ﬁnd-
ings occluded without intervention (P ¼ .0001; Fig).
Excluding the eight patients who underwent prophylactic
intervention, seven of 12 grafts with abnormal DU ﬁndings
went on to occlude without intervention vs two of 72 with
normal DU ﬁndings (P ¼ .0001). The sensitivity of DU
(number of occluded stent grafts associated with an
abnormal study) for the total cohort was 58% (seven of
Abnormal DU Findings Undergoing Prophylactic Intervention or 
Occluding  
Iliac Arteries
Femoro-Popliteal Arteries
Infrainguinal Bypass
Grafts
Fig. Abnormal duplex ultrasound (DU) ﬁndings of arterial seg-
ments undergoing prophylactic intervention or that have occluded.
Table V. Stent graft patency in the total cohort based on
normal vs abnormal duplex ultrasound (DU) ﬁndingsa
Variable
DU ﬁnding
Total, No.Normal, No. Abnormal, No.
Patent 70 5 75
Occluded 2 7 9
Total 72 12 84
aFisher exact test P ¼ .0001; sensitivity, 7 of 12 (58%); speciﬁcity, 70 of 72
(97%); positive predictive value, 7 of 9 (78%); and negative predictive value,
70 of 75 (93%).
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a normal DU study) was 97% (70 of 72). The negative
predictive value (number of normal studies that correctly
predicted a patent stent graft) and positive predictive value
(number of abnormal studies that correctly predicted an
occluded stent graft) for the total cohort was 78% (seven
of eight) and 93% (70 of 75), respectively (Table V).
The statistically signiﬁcant markers for stent graft fail-
ure compared with the normal DU cohort were PSVs
>300 cm/s (P ¼ .0194), Vr >3.0 (P ¼ .0279), and uni-
form PSVs <50 cm/s (P ¼ .0001). To determine the
criteria that were most sensitive in predicting stent graft
thrombosis, the sensitivity (number of occluded stent grafts
associated with an abnormal study) was calculated for all of
the individually abnormal DU ﬁndings. PSVs >300 cm/s
had a sensitivity of 40%, Vr >3.0 had a sensitivity of 33%,
and uniform PSVs <50 cm/s, with a value of 83%, was
the most sensitive predictor of stent graft failure.DISCUSSION
Use of stent grafts (ie covered stents) placed for arterial
occlusive disease of the lower extremity has increased. The
VIPER (Viabahn Endoprosthesis with Heparin Bioactive
Surface in the Treatment of Superﬁcial Femoral Artery
Obstructive Disease) and VIASTAR (Viabahn endopros-
thesis with Propaten bioactive surface [VIA] vs bare nitinol
stent in the treatment of long lesions in superﬁcial femoral
artery occlusive disease) trials showed that stent grafts have
better patency rates than bare-metal stents for treatment of
long femoropopliteal lesions.
The VIPER trial showed primary and secondary
patency rates of 73% and 92%, respectively. This trial
showed better patency rates for covered stents compared
with historical controls reported for bare-metal stents
used to treat long femoropopliteal lesions.6 The VIASTAR
trial was a randomized study that had primary and second-
ary patency rates of 78.1% and 89.9%, respectively, for
covered stent grafts compared with 53.5% and 75.2%,
respectively, for bare-metal stents.7 Both of these trials
used self-expanding nitinol, heparin-bonded stent grafts.Stent grafts have also demonstrated better patency rates
compared with historical controls in the iliac artery segment
compared with bare-metal stents for extensive (ie, TASC C
and D) occlusive disease. Rzucidlo et al8 showed 1-year pri-
mary and assisted primary patency rates of 70% and 88%,
respectively, for complex TASC C and D lesions.
As a result of these recent publications, we have used
stents grafts more liberally for the treatment of lower
extremity occlusive disease. We prefer stent grafts in the
iliac artery for stenotic lesions that have restenosed, are
heavily calciﬁed, and in our opinion, are particularly prone
to embolization. In the femoropopliteal segment, we prefer
stent grafts for long occlusive lesions, restenosis, heavy
calciﬁcation, larger diameter (>5 mm) arteries, and lesions
that may be prone to embolization in our opinion. We have
used stent grafts in a few patients with long stenoses in vein
bypass grafts to maintain graft patency, especially if the ste-
nosis was located in a scarred groin in obese patients or for
anatomically tunneled grafts. We only use stent grafts when
treating long stenoses in larger-diameter failing vein grafts,
namely >5 mm.
Use of stent grafts to treat lower extremity occlusive
disease is increasing. DU surveillance may prove useful to
help maintain patency of these conduits should they
develop stenotic lesions. A few authors have reported DU
criteria for diagnosing arterial stenoses, postballoon angio-
plasty stenoses, and bare-metal stents that developed
intimal hyperplasia or partial collapse. Baril et al9 used a
linear regression model of PSVs and Vr to determine DU
criteria that were sensitive and speciﬁc for in-stent resteno-
sis of the femoropopliteal artery. They determined a PSV
>275 cm/s or a Vr >3.5 was highly speciﬁc and predictive
of an 80% stenosis.6 Khan et al10 performed a similar anal-
ysis to establish DU criteria for de novo lesions. They
showed a PSV >200 cm/s or a Vr >2.0 was accurate in
detecting >70% stenosis of the femoropopliteal artery.
These studies provided a range of DU criteria to help guide
a physician in determining restenosis of native arteries.
We previously reported DU surveillance for lower
extremity vein and prosthetic bypass grafts.1-3 We applied
these criteria for diagnosing a failing stent graft and deﬁned
“abnormal DU ﬁndings” as focal PSVs>300 cm/s, uniform
PSVs <50 cm/s, or Vr >3.0. When we retrospectively
reviewed ourDUdata on stent grafts, we did not have angio-
graphicmeasurements to perform a linear regression analysis
JOURNAL OF VASCULAR SURGERY
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certain stenosis. When all of these “abnormal DU ﬁndings”
were considered, the sensitivity for a stent graft to occlude
was 58% but the speciﬁcity was 97%. Although all of the in-
dividual “abnormal DU ﬁndings” were statistical predictors
of stent graft thrombosis, a uniform PSV<50 cm/s was the
most sensitive predictor of failure. This coincides with DU
data published by Kallakuri et al12 that demonstrated lower
ﬂow rates are associated with higher rates of thrombosis in
lower extremity prosthetic grafts.
If DU studies for a lower extremity bypass graft are
normal after 1 year, then most authorities recommend
performing annual surveillance studies thereafter, because
grafts after this time are considered at a lower risk for occlu-
sion. We have continued to perform surveillance studies
every 6 months after the ﬁrst year for endovascular inter-
ventions. The patency of endovascular interventions is typi-
cally less than that of surgical bypasses, and the natural
history of stent graft failure is unknown. We therefore
believe a more frequent surveillance protocol after 1 year
is reasonable until longer follow-up data can be generated.
Interventionalists may question whether surveying and
then treat failing peripheral stent grafts is worthwhile. We
believe there are several valid reasons to intervene prophy-
lactically before the stent graft occludes or before the
patient becomes symptomatic:
First, it is likely to be much more difﬁcult, if not impos-
sible, to cross an occluded, rather than stenotic stent graft.
Second, the chance of embolization is likely higher
when intervening for an occluded rather than a stenotic
stent graft due to the presence of thrombus in the occluded
stent graft and the need for increased manipulation of cath-
eters and wires.
Third, generally these prophylactic interventions can be
performed electively instead of having to be done as an
emergency if acute rest pain occurs when the stent graft
occludes.
Fourth, if the stent graft was inserted to salvage a
failing vein graft, the entire vein graft may thrombose if
intervention is not performed and the vein graft may be
irretrievably lost. Intervention should be tailored to the
arterial bed being treated.
Because uniform PSVs <50 cm/s were the most sensi-
tive predictor of failure, we believe these lesions should be
preferentially undergo intervention. However, there may
not be any endovascular treatment options for lesions
with a PSV <50 cm/s (ie, more proximal disease may
need intervention).
Limitations of this study include the relatively small
sample size and variety of arterial beds being compared.
The data were retrospectively reviewed, therefore a pro-
spective randomized study of the outcomes of failing stent
grafts that undergo intervention based on our criteria for
stent grafts compared with those that do not undergo
surveillance and prophylactic intervention would provide
more clarity.
We also emphasize that these results were based on
ﬁndings reported by highly skilled technologists in anIntersocietal Accreditation Commission-accredited nonin-
vasive vascular laboratory that is devoted to duplex surveil-
lance not only of peripheral interventions but also aortic
stent grafts and other vascular interventions.13-15 There
will always be some variation between different laboratories
when comparing DU measurements. Lastly, DU surveil-
lance of stent grafts may also be limited by the patient’s
habitus, dense calciﬁcations, or prior surgeries, or a combi-
nation of these.
CONCLUSIONS
These ﬁndings suggest that follow-up DU surveillance
can predict failure of stent grafts placed for lower extremity
arterial occlusive disease. Focal PSVs >300 cm/s, Vr >3.0,
andmost importantly, uniform PSVs<50 cm/s throughout
the stent graft were statistically reliable markers for predict-
ing stent graft thrombosis. We recommend aggressive
surveillance protocols to follow peripheral stent grafts
accompanied by aggressive intervention tomaintain patency
and avoid acute stent graft thrombosis.
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